Interferon regulatory factor-5 deficiency ameliorates disease severity in the MRL/lpr mouse model of lupus in the absence of a mutation in DOCK2

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Yasuda, Kei ^a   Watkins, Amanda A ^a   Kochar, Guneet S ^a   Wilson, Gabriella E ^a   Laskow, Bari ^a   Richez, Christophe ^a   Bonegio, Ramon G ^a   Rifkin, Ian R ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERFERON REGULATORY FACTOR 5; AUTOANTIBODY; B CELL ACTIVATING FACTOR; DOCK2 PROTEIN, MOUSE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; IMMUNOGLOBULIN CLASS; INTERFERON REGULATORY FACTOR; IRF5 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; DISEASE SEVERITY; DOCK2 GENE; GENE; GENE MUTATION; HETEROZYGOSITY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; BLOOD; C57BL MOUSE; CYTOLOGY; DEFICIENCY; DISEASE MODEL; GENETICS; IMMUNOLOGY; KIDNEY DISEASE; KNOCKOUT MOUSE; METABOLISM; MORTALITY; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; MUTATION; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SPLEEN; SURVIVAL ANALYSIS; TH1 CELL;

ANIMALS; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GTPASE-ACTIVATING PROTEINS; IMMUNOGLOBULIN ISOTYPES; INTERFERON REGULATORY FACTORS; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MICE, KNOCKOUT; MUTATION; SEVERITY OF ILLNESS INDEX; SPLEEN; SURVIVAL ANALYSIS; TH1 CELLS;

EID: 84905024384     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103478     Document Type: Article

References (53)

1. Liu Z, Davidson A (2012) Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med 18: 871-882.
2. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, et al. (2005) Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 76: 528-537. (Pubitemid 40250533)
3. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, et al. (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38: 550-555.
4. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, et al. (2007) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 104: 6758-6763. (Pubitemid 47175574)
5. Harley IT, Kaufman KM, Langefeld CD, Harley JB, Kelly JA (2009) Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet 10: 285-290.
6. Graham DS, Manku H, Wagner S, Reid J, Timms K, et al. (2007) Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum Mol Genet 16: 579-591. (Pubitemid 46585660)
7. Ferreiro-Neira I, Calaza M, Alonso-Perez E, Marchini M, Scorza R, et al. (2007) Opposed independent effects and epistasis in the complex association of IRF5 to SLE. Genes Immun 8: 429-438. (Pubitemid 47177133)
8. Feng D, Stone RC, Eloranta ML, Sangster-Guity N, Nordmark G, et al. (2010) Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum 62: 562-573.
9. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, et al. (2008) Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 58: 2481-2487.
10. Sigurdsson S, Goring HH, Kristjansdottir G, Milani L, Nordmark G, et al. (2008) Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 17: 872-881. (Pubitemid 351368993)
11. Hedl M, Abraham C (2012) IRF5 risk polymorphisms contribute to interindividual variance in pattern recognition receptor-mediated cytokine secretion in human monocyte-derived cells. J Immunol 188: 5348-5356.
12. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, et al. (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434: 243-249. (Pubitemid 40388058)
13. Yasuda K, Richez C, Maciaszek JW, Agrawal N, Akira S, et al. (2007) Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol 178: 6876-6885. (Pubitemid 46847413)
14. Savitsky DA, Yanai H, Tamura T, Taniguchi T, Honda K (2010) Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proc Natl Acad Sci U S A 107: 10154-10159.
15. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, et al. (2005) The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem 280: 17005-17012. (Pubitemid 41389162)
16. Paun A, Reinert JT, Jiang Z, Medin C, Balkhi MY, et al. (2008) Functional characterization of murine interferon regulatory factor 5 (IRF-5) and its role in the innate antiviral response. J Biol Chem 283: 14295-14308.
17. Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, et al. (2007) Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci U S A 104: 3402-3407. (Pubitemid 46364171)
18. Yasuda K, Nundel K, Watkins AA, Dhawan T, Bonegio RG, et al. (2013) Phenotype and function of B cells and dendritic cells from interferon regulatory factor 5-deficient mice with and without a mutation in DOCK2. Int Immunol 25: 295-306.
19. Couzinet A, Tamura K, Chen HM, Nishimura K, Wang Z, et al. (2008) A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis. Proc Natl Acad Sci U S A 105: 2556-2561. (Pubitemid 351520552)
20. Hu G, Barnes BJ (2009) IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway. J Biol Chem 284: 2767-2777.
21. Richez C, Yasuda K, Bonegio RG, Watkins AA, Aprahamian T, et al. (2010) IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/- Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus. J Immunol 184: 796-806.
22. Tada Y, Kondo S, Aoki S, Koarada S, Inoue H, et al. (2011) Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice. Arthritis Rheum 63: 738-748.
23. Feng D, Yang L, Bi X, Stone RC, Patel P, et al. (2012) Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching. Eur J Immunol 42: 1477-1487.
24. Xu Y, Lee PY, Li Y, Liu C, Zhuang H, et al. (2012) Pleiotropic IFN-dependent and -independent effects of IRF5 on the pathogenesis of experimental lupus. J Immunol 188: 4113-4121.
25. Purtha WE, Swiecki M, Colonna M, Diamond MS, Bhattacharya D (2012) Spontaneous mutation of the Dock2 gene in Irf5-/- mice complicates interpretation of type I interferon production and antibody responses. Proc Natl Acad Sci U S A 109: E898-904.
26. Fukui Y, Hashimoto O, Sanui T, Oono T, Koga H, et al. (2001) Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 412: 826-831. (Pubitemid 32801465)
27. Nishikimi A, Fukuhara H, Su W, Hongu T, Takasuga S, et al. (2009) Sequential regulation of DOCK2 dynamics by two phospholipids during neutrophil chemotaxis. Science 324: 384-387.
28. Tanaka Y, Hamano S, Gotoh K, Murata Y, Kunisaki Y, et al. (2007) T helper type 2 differentiation and intracellular trafficking of the interleukin 4 receptoralpha subunit controlled by the Rac activator Dock2. Nat Immunol 8: 1067-1075. (Pubitemid 47423754)
29. Gotoh K, Tanaka Y, Nishikimi A, Nakamura R, Yamada H, et al. (2010) Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. J Exp Med 207: 721-730.
30. Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, et al. (2012) Lupus nephritis: a critical review. Autoimmun Rev 12: 174-194.
31. Bellomo R, Kellum JA, Ronco C (2012) Acute kidney injury. Lancet 380: 756-766.
32. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, et al. (1978) Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 148: 1198-1215. (Pubitemid 9053639)
33. Cash H, Relle M, Menke J, Brochhausen C, Jones SA, et al. (2010) Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol 37: 60-70.
34. Stohl W, Hilbert DM (2012) The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol 30: 69-77.
35. Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, et al. (2007) BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 204: 1959-1971. (Pubitemid 47236330)
36. Douagi I, Gujer C, Sundling C, Adams WC, Smed-Sorensen A, et al. (2009) Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J Immunol 182: 1991-2001.
37. Panchanathan R, Choubey D (2013) Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity. Mol Immunol 53: 15-23.
38. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, et al. (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995-999. (Pubitemid 30243593)
39. Lien C, Fang CM, Huso D, Livak F, Lu R, et al. (2010) Critical role of IRF-5 in regulation of B-cell differentiation. Proc Natl Acad Sci U S A 107: 4664-4668.
40. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV (2006) TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 203: 553-561.
41. Baudino L, Azeredo da Silveira S, Nakata M, Izui S (2006) Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies. Springer Semin Immunopathol 28: 175-184. (Pubitemid 46628484)
42. Takahashi S, Nose M, Sasaki J, Yamamoto T, Kyogoku M (1991) IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis. J Immunol 147: 515-519.
43. Greenspan NS, Lu MA, Shipley JW, Ding X, Li Q, et al. (2012) IgG3 deficiency extends lifespan and attenuates progression of glomerulonephritis in MRL/lpr mice. Biol Direct 7: 3.
44. Nickerson KM, Christensen SR, Shupe J, Kashgarian M, Kim D, et al. (2010) TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 184: 1840-1848.
45. Victora GD, Nussenzweig MC (2012) Germinal centers. Annu Rev Immunol 30: 429-457.
46. Brink R (2014) The imperfect control of self-reactive germinal center B cells. Curr Opin Immunol 28C: 97-101.
47. Panchanathan R, Liu H, Fang CM, Erickson LD, Pitha PM, et al. (2011) Distinct Regulation of Murine Lupus Susceptibility Genes by the IRF5/Blimp-1 Axis. J Immunol.
48. Shapiro-Shelef M, Calame K (2005) Regulation of plasma-cell development. Nat Rev Immunol 5: 230-242. (Pubitemid 40364824)
49. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, et al. (2011) IRF5 promotes inflammatory macrophage polarization and T(H)1-T(H)17 responses. Nat Immunol 12: 231-238.
50. Steinhagen F, McFarland AP, Rodriguez LG, Tewary P, Jarret A, et al. (2013) IRF-5 and NF-kappaB p50 co-regulate IFN-beta and IL-6 expression in TLR9-stimulated human plasmacytoid dendritic cells. Eur J Immunol 43: 1896-1906.
51. Mancl ME, Hu G, Sangster-Guity N, Olshalsky SL, Hoops K, et al. (2005) Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J Biol Chem 280: 21078-21090. (Pubitemid 40805667)
52. Bronson PG, Chaivorapol C, Ortmann W, Behrens TW, Graham RR (2012) The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol 24: 530-537.
53. Castigli E, Wilson SA, Scott S, Dedeoglu F, Xu S, et al. (2005) TACI and BAFFR mediate isotype switching in B cells. J Exp Med 201: 35-39. (Pubitemid 40130081)